• Galderma flagged new three-year Nemluvio data for atopic dermatitis, scheduled for presentation at the 2026 Fall Clinical Dermatology Conference.
• A post-hoc analysis indicated early responders maintained durable skin improvement and itch control through three years of continued treatment.
• A separate interim analysis in a broader long-term extension population reinforced sustained symptom relief and a consistent safety profile over three years.
• Management positioned the readouts as supporting longer-term disease control, a key differentiator in competitive inflammatory dermatology markets.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galderma Group AG published the original content used to generate this news brief via Business Wire (Ref. ID: 20261007414473) on October 08, 2026, and is solely responsible for the information contained therein.